Skip to main content

Ernexa Therapeutics Inc.

ERNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000748592

No open-market purchases or sales by Ernexa Therapeutics Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $236.2K in total; no superinvestor holds it.

Other share classesERNAW

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −10 vs. previous quarter
10
13F valueReported value at the end of Q2 2026
$236.2K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ERNA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ERNA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Ernexa Therapeutics Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 17, 2026 (view filing)Feb 107 daysLateCherington Charles10% OwnerPPurchase+4.00M$0.50+$2.00M+143.9%6.78M after
Feb 17, 2026 (view filing)Feb 107 daysLateCherington Charles10% OwnerPPurchase+4.00M–––4.00M afterDerivative
Jun 11, 2025 (view filing)8:34 PM ETJun 92 daysCherington Charles10% OwnerPPurchase+21.2M$0.1046+$2.22M+104.0%41.7M after
May 7, 2025 (view filing)11:48 AM ETSep 24, 2024225 daysCherington Charles10% OwnerPPurchase+13.3M––+2,381.5%13.8M afterAmended5 lots
May 7, 2025 (view filing)11:48 AM ETSep 24, 2024225 daysCherington Charles10% OwnerSSale−10.5M–––0 afterAmendedDerivative5 lots
Apr 4, 2025 (view filing)10:54 AM ETApr 22 daysCherington Charles10% OwnerPPurchase+3.77M$0.1046+$394.2K+22.7%20.4M after
Dec 20, 2023 (view filing)10:05 AM ETDec 146 daysLateCherington Charles10% OwnerPPurchase+7.52M$0.0833+$390.7K–523.5K afterDerivative4 lotsPrice outlier
Dec 18, 2023 (view filing)9:38 PM ETDec 153 daysHuff Curtis W and 2 others10% OwnerPPurchaseCommon Stock, par value $0.005 per share+1.56M$1.92+$1.00M–1.99M afterDerivative2 lots
Aug 25, 2023 (view filing)7:34 PM ETJul 1343 daysLateCherington Charles10% OwnerPPurchase+3.46M$0.0833+$288.5K–2.31M afterDerivative2 lotsPrice outlier
Jul 18, 2023 (view filing)4:15 PM ETJul 135 daysLateBinder BrantDirectorPPurchase+125.9K$0.0833+$10.5K–83.9K afterDerivative2 lotsPrice outlier

Top 10 13F holders, Q2 2026

The largest institutional positions in Ernexa Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 10 holders
Institutions holding ERNA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Citadel Advisors LLC15,104$100.4K0.00%−17,972−54.3%Reduced
Vanguard Fiduciary Trust Co8,336$55.4K0.00%−17,111−67.2%Reduced
Dauntless Investment Group, LLC6,000$39.9K0.07%−606,443−99.0%Reduced
Vanguard Capital Management LLC5,684$37.8K0.00%−20,820−78.6%Reduced
Tradewinds Capital Management, LLC361$2.40K0.00%+361New
BlackRock, Inc.33$2190.00%−787−96.0%Reduced
Assetmark, Inc5$330.00%−128−96.2%Reduced
BNP Paribas Arbitrage, SA1$70.00%−9−90.0%Reduced
SBI Securities Co., Ltd.1$70.00%−5−83.3%Reduced
Steward Partners Investment Advisory, LLC0$10.00%0New